Folgen
Christian Labenz
Christian Labenz
University Medical Center Mainz
Bestätigte E-Mail-Adresse bei unimedizin-mainz.de
Titel
Zitiert von
Zitiert von
Jahr
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
FE Mózes, JA Lee, EA Selvaraj, ANA Jayaswal, M Trauner, J Boursier, ...
Gut 71 (5), 1006-1019, 2022
2632022
Predictors of advanced fibrosis in non‐cirrhotic non‐alcoholic fatty liver disease in Germany
C Labenz, Y Huber, E Kalliga, M Nagel, C Ruckes, BK Straub, PR Galle, ...
Alimentary pharmacology & therapeutics 48 (10), 1109-1116, 2018
1162018
Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation
Y Huber, M Boyle, K Hallsworth, D Tiniakos, BK Straub, C Labenz, ...
Clinical Gastroenterology and Hepatology 17 (10), 2085-2092. e1, 2019
1032019
Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany
C Labenz, Y Huber, M Michel, M Nagel, PR Galle, K Kostev, ...
Digestive diseases and sciences 65, 2112-2119, 2020
912020
Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients
C Labenz, JS Baron, G Toenges, JM Schattenberg, M Nagel, MF Sprinzl, ...
Alimentary Pharmacology & Therapeutics 48 (3), 313-321, 2018
862018
Improvement of non‐invasive markers of NAFLD from an individualised, web‐based exercise program
Y Huber, D Pfirrmann, I Gebhardt, C Labenz, N Gehrke, BK Straub, ...
Alimentary Pharmacology & Therapeutics 50 (8), 930-939, 2019
852019
Nonalcoholic fatty liver disease increases the risk of anxiety and depression
C Labenz, Y Huber, M Michel, M Nagel, PR Galle, K Kostev, ...
Hepatology Communications 4 (9), 1293-1301, 2020
802020
Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease
L Kaps, C Labenz, PR Galle, J Weinmann-Menke, K Kostev, ...
United European Gastroenterology Journal 8 (8), 942-948, 2020
582020
Health-related quality of life in patients with compensated and decompensated liver cirrhosis
C Labenz, G Toenges, JM Schattenberg, M Nagel, Y Huber, JU Marquardt, ...
European journal of internal medicine 70, 54-59, 2019
542019
Clinical Frailty Scale for risk stratification in patients with SARS-CoV-2 infection
C Labenz, WM Kremer, JM Schattenberg, MA Wörns, G Toenges, ...
Journal of Investigative Medicine 68 (6), 1199-1202, 2020
462020
Adipokines and endotoxemia correlate with hepatic steatosis in non-alcoholic fatty liver disease (NAFLD)
A Nier, Y Huber, C Labenz, M Michel, I Bergheim, JM Schattenberg
Nutrients 12 (3), 699, 2020
462020
Incident dementia in elderly patients with nonalcoholic fatty liver disease in Germany
C Labenz, K Kostev, L Kaps, PR Galle, JM Schattenberg
Digestive diseases and sciences 66 (9), 3179-3185, 2021
402021
Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy
C Labenz, G Toenges, Y Huber, M Nagel, JU Marquardt, JM Schattenberg, ...
Alimentary Pharmacology & Therapeutics 50 (10), 1112-1119, 2019
402019
Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy
C Labenz, L Beul, G Toenges, JM Schattenberg, M Nagel, MF Sprinzl, ...
European Journal of Internal Medicine 60, 96-100, 2019
392019
Patterns of liver injury in COVID-19–a German case series
JM Schattenberg, C Labenz, MA Woerns, P Menge, A Weinmann, ...
United European Gastroenterology Journal 8 (7), 814-819, 2020
352020
Cardiovascular risk categories in patients with nonalcoholic fatty liver disease and the role of Low‐Density lipoprotein cholesterol
C Labenz, JH Prochaska, Y Huber, M Nagel, BK Straub, P Wild, PR Galle, ...
Hepatology Communications 3 (11), 1472-1481, 2019
352019
Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2
M Nguyen-Tat, J Jäger, JW Rey, M Nagel, C Labenz, MA Wörns, PR Galle, ...
United European gastroenterology journal 7 (4), 529-537, 2019
352019
Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL
C Labenz, A Arslanow, M Nguyen-Tat, M Nagel, MA Wörns, MC Reichert, ...
Journal of Hepatology 77 (3), 695-701, 2022
342022
Tumor incidence in patients with non-alcoholic fatty liver disease
Y Huber, C Labenz, M Michel, MA Wörns, PR Galle, K Kostev, ...
Deutsches Ärzteblatt International 117 (43), 719, 2020
342020
Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis
C Labenz, M Nagel, WM Kremer, M Hilscher, CA Schilling, G Toenges, ...
Alimentary pharmacology & therapeutics 52 (3), 527-536, 2020
342020
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20